Supplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 5: Tolerability of 40 mg/kg elimusertib
Authors: Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso, Yasmeen Qamar Rizvi, Xiaofeng Zheng, Dhruv Chachad, Timothy P. DiPeri, Bailiang Wang, Stephen M. Scott, Ming Zhao, Argun Akcakanat, Antje M. Wengner, Timothy A. Yap, Funda Meric-Bernstam
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4413905573